Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive

You may also be interested in...



California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China

BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments

California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China

BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments

Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel